We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Ultrasound Aspiration Needle Investigates Gastrointestinal Lesions

By HospiMedica International staff writers
Posted on 24 May 2011
An innovative endoscopic biopsy system based on fine needle aspiration (FNA) technology expands diagnostic capabilities in the pancreas and gastrointestinal (GI) tract.

The Expect Endoscopic Ultrasound (EUS) aspiration needle is designed to collect tissue samples from both submucosal and extramural gastrointestinal (GI) lesions, helps clinicians diagnose and stage malignancies in organs adjacent to the GI tract. More...
The Expect needle features an echogenic pattern providing excellent visibility and precise needle guidance within the targeted organ or structure. A chromium-cobalt-alloy design is engineered to offer improved sharpness and pushability, along with deformation resistance, compared to traditional stainless steel needles. As a result, physicians may be able to obtain more easily and accurately a tissue sample while maintaining excellent visibility during the procedure, thanks to an etched pattern on the needle that makes it clearly visible under ultrasound.

The echogenic pattern is also responsible for the improved penetration of the lesion sheath, thus providing a smoother passage through the scope and controlled needle actuation. An ergonomic handle with a slip-resistant grip helps maintain controlled needle penetration with a shorter, wider design. Sheath length and needle depth adjustment can be locked to the stylet, which remains coiled and in place for improved handling between needle passes. The Expect Endoscopic Ultrasound (EUS) aspiration needle is a product of Boston Scientific (Natick, MA, USA), and has received both US Food and Drug Administration (FDA) clearance and the European Community (CE) mark of approval.

"The quality of tissue samples is critical to accurately assessing malignancies, which in turn impact treatment algorithms," said Shyam Varadarajulu, MD, director of endoscopy at the University of Alabama (Birmingham, USA). "The Expect Needle yields detailed, high-quality samples that enable rapid evaluation of lesions and abnormalities to determine the specific stage of malignancies."

"The launch of the Expect needle broadens our endoscopy portfolio and further strengthens our leadership position in pancreaticobiliary disease management," said David Pierce, president of Boston Scientific's endoscopy division. "Providing physicians with an innovative, durable aspiration needle for EUS-FNA procedures highlights our commitment to delivering a full suite of advanced technologies to diagnose gastrointestinal diseases and help improve patient care."

EUS is a nonsurgical, less-invasive procedure that uses high-frequency sound waves to produce detailed images of the GI tract and adjacent organs, including the pancreas, liver, bile duct, and mediastinal space. To complement EUS, FNA is often used to collect cytology samples for cancer diagnosis. Data have shown that EUS is associated with improved survival rates for pancreatic cancer patients due to more informed, stage-appropriate disease management.

Related Links:

Boston Scientific




Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.